What are the key commercial and ethical considerations of new genetic technologies, from the standpoint of all stakeholders?
What are the key commercial and ethical considerations of new genetic technologies, from the standpoint of all stakeholders?
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) came to the spotlight in the early 2000s when scientists discovered the potential to use CRISPR’s associated Cas9 enzyme as molecular “scissors” to edit existing genetic sequences. For Neurosplice Biosciences, one particular potential treatment focus of CRISPR-Cas9 research has been on Alzheimer’s disease (AD), a devastating progressive neurological disease with dismal outcomes and a potential genetic link. However, the use of this new technology has been met with heated criticisms and regulatory hurdles. In this case, students will learn about genetic technologies and discuss the commercial opportunity as well as ethical concerns surrounding CRISPR-based therapies.
About the Author(s)
